PACIFIC BIOSCIENCES OF CALIFORNIA, INC. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that PACIFIC BIOSCIENCES OF CALIFORNIA, INC. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Dec 31, 2017 | $24.94M | Feb 26, 2018 |
| FY2017 | Sep 30, 2017 | $23.55M | Feb 26, 2018 |
| FY2017 | Jun 30, 2017 | $20.07M | Feb 26, 2018 |
| FY2017 | Mar 31, 2017 | $24.92M | Feb 26, 2018 |
| FY2017 | Dec 31, 2016 | $25.72M | Feb 26, 2018 |
| FY2017 | Sep 30, 2016 | $25.12M | Feb 26, 2018 |
| FY2017 | Jun 30, 2016 | $20.75M | Feb 26, 2018 |
| FY2017 | Mar 31, 2016 | $19.13M | Feb 26, 2018 |
| FY2016 | Dec 31, 2015 | $36.28M | Mar 6, 2017 |
| FY2016 | Sep 30, 2015 | $13.92M | Mar 6, 2017 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2018 | Dec 31, 2018 | $78.63M | Feb 26, 2019 |
| FY2018 | Dec 31, 2017 | $93.47M | Feb 26, 2019 |
| FY2018 | Dec 31, 2016 | $90.71M | Feb 26, 2019 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $45.78M | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | $37.28M | Feb 25, 2026 |
| FY2025 | Dec 31, 2023 | $52.78M | Feb 25, 2026 |
| FY2024 | Dec 31, 2022 | $49.04M | Mar 17, 2025 |
| FY2023 | Dec 31, 2021 | $58.86M | Feb 28, 2024 |
| FY2022 | Dec 31, 2020 | $32.57M | Feb 28, 2023 |
| FY2019 | Dec 31, 2019 | $12.93M | Feb 28, 2020 |
| FY2019 | Sep 30, 2019 | $6.91M | Feb 28, 2020 |
| FY2019 | Jun 30, 2019 | $9.61M | Feb 28, 2020 |
| FY2019 | Mar 31, 2019 | $5.12M | Feb 28, 2020 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($546.38M) | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | ($309.85M) | Feb 25, 2026 |
| FY2025 | Dec 31, 2023 | ($306.74M) | Feb 25, 2026 |
| FY2024 | Dec 31, 2022 | ($314.25M) | Mar 17, 2025 |
| FY2023 | Dec 31, 2021 | ($181.22M) | Feb 28, 2024 |
| FY2022 | Dec 31, 2020 | $29.40M | Feb 28, 2023 |
| FY2019 | Dec 31, 2019 | ($91.0K) | Feb 28, 2020 |
| FY2019 | Sep 30, 2019 | ($29.12M) | Feb 28, 2020 |
| FY2019 | Jun 30, 2019 | ($24.60M) | Feb 28, 2020 |
| FY2019 | Mar 31, 2019 | ($30.32M) | Feb 28, 2020 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($553.86M) | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | ($474.31M) | Feb 25, 2026 |
| FY2025 | Dec 31, 2023 | ($334.47M) | Feb 25, 2026 |
| FY2024 | Dec 31, 2022 | ($307.20M) | Mar 17, 2025 |
| FY2023 | Dec 31, 2021 | ($210.44M) | Feb 28, 2024 |
| FY2022 | Dec 31, 2020 | ($104.39M) | Feb 28, 2023 |
| FY2019 | Dec 31, 2019 | ($17.92M) | Feb 28, 2020 |
| FY2019 | Sep 30, 2019 | ($28.11M) | Feb 28, 2020 |
| FY2019 | Jun 30, 2019 | ($24.38M) | Feb 28, 2020 |
| FY2019 | Mar 31, 2019 | ($30.13M) | Feb 28, 2020 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $97.31M | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | $134.92M | Feb 25, 2026 |
| FY2025 | Dec 31, 2023 | $187.17M | Feb 25, 2026 |
| FY2024 | Dec 31, 2022 | $193.00M | Mar 17, 2025 |
| FY2023 | Dec 31, 2021 | $112.90M | Feb 28, 2024 |
| FY2022 | Dec 31, 2020 | $64.15M | Feb 28, 2023 |
| FY2021 | Dec 31, 2019 | $59.63M | Feb 28, 2022 |
| FY2020 | Dec 31, 2018 | $62.59M | Feb 26, 2021 |
| FY2019 | Dec 31, 2017 | $65.32M | Feb 28, 2020 |
| FY2018 | Dec 31, 2016 | $67.62M | Feb 26, 2019 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $141.49M | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | $175.02M | Feb 25, 2026 |
| FY2025 | Dec 31, 2023 | $169.82M | Feb 25, 2026 |
| FY2024 | Dec 31, 2022 | $160.85M | Mar 17, 2025 |
| FY2023 | Dec 31, 2021 | $124.12M | Feb 28, 2024 |
| FY2022 | Dec 31, 2020 | $72.80M | Feb 28, 2023 |
| FY2021 | Dec 31, 2019 | $75.49M | Feb 28, 2022 |
| FY2020 | Dec 31, 2018 | $63.49M | Feb 26, 2021 |
| FY2019 | Dec 31, 2017 | $59.12M | Feb 28, 2020 |
| FY2018 | Dec 31, 2016 | $47.79M | Feb 26, 2019 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($111.21M) | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | ($206.06M) | Feb 25, 2026 |
| FY2025 | Dec 31, 2023 | ($259.17M) | Feb 25, 2026 |
| FY2024 | Dec 31, 2022 | ($263.21M) | Mar 17, 2025 |
| FY2023 | Dec 31, 2021 | ($111.18M) | Feb 28, 2024 |
| FY2022 | Dec 31, 2020 | $19.50M | Feb 28, 2023 |
| FY2021 | Dec 31, 2019 | ($78.31M) | Feb 28, 2022 |
| FY2020 | Dec 31, 2018 | ($66.43M) | Feb 26, 2021 |
| FY2019 | Dec 31, 2017 | ($67.52M) | Feb 28, 2020 |
| FY2018 | Dec 31, 2016 | ($67.93M) | Feb 26, 2019 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.71M | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | $6.19M | Feb 25, 2026 |
| FY2025 | Dec 31, 2023 | $8.84M | Feb 25, 2026 |
| FY2024 | Dec 31, 2022 | $16.75M | Mar 17, 2025 |
| FY2023 | Dec 31, 2021 | $5.93M | Feb 28, 2024 |
| FY2022 | Dec 31, 2020 | $1.04M | Feb 28, 2023 |
| FY2021 | Dec 31, 2019 | $2.84M | Feb 28, 2022 |
| FY2020 | Dec 31, 2018 | $1.85M | Feb 26, 2021 |
| FY2019 | Dec 31, 2017 | $10.43M | Feb 28, 2020 |
| FY2018 | Dec 31, 2016 | $8.21M | Feb 26, 2019 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $784.08M | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | $1.26B | Feb 25, 2026 |
| FY2024 | Dec 31, 2023 | $1.75B | Mar 17, 2025 |
| FY2023 | Dec 31, 2022 | $1.77B | Feb 28, 2024 |
| FY2022 | Dec 31, 2021 | $2.01B | Feb 28, 2023 |
| FY2021 | Dec 31, 2020 | $413.98M | Feb 28, 2022 |
| FY2020 | Dec 31, 2019 | $147.99M | Feb 26, 2021 |
| FY2019 | Dec 31, 2018 | $170.28M | Feb 28, 2020 |
| FY2018 | Dec 31, 2017 | $144.08M | Feb 26, 2019 |
| FY2017 | Dec 31, 2016 | $137.88M | Feb 26, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $778.73M | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | $753.85M | Feb 25, 2026 |
| FY2024 | Dec 31, 2023 | $1.04B | Mar 17, 2025 |
| FY2023 | Dec 31, 2022 | $1.20B | Feb 28, 2024 |
| FY2022 | Dec 31, 2021 | $1.22B | Feb 28, 2023 |
| FY2021 | Dec 31, 2020 | $78.49M | Feb 28, 2022 |
| FY2020 | Dec 31, 2019 | $93.07M | Feb 26, 2021 |
| FY2019 | Dec 31, 2018 | $56.21M | Feb 28, 2020 |
| FY2018 | Dec 31, 2017 | $57.98M | Feb 26, 2019 |
| FY2017 | Dec 31, 2016 | $53.22M | Feb 26, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $5.35M | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | $506.59M | Feb 25, 2026 |
| FY2025 | Dec 31, 2023 | $701.30M | Feb 25, 2026 |
| FY2025 | Dec 31, 2022 | $562.90M | Feb 25, 2026 |
| FY2024 | Dec 31, 2021 | $790.99M | Mar 17, 2025 |
| FY2023 | Dec 31, 2020 | $335.49M | Feb 28, 2024 |
| FY2022 | Dec 31, 2019 | $54.92M | Feb 28, 2023 |
| FY2021 | Dec 31, 2018 | $114.06M | Feb 28, 2022 |
| FY2020 | Dec 31, 2017 | $86.10M | Feb 26, 2021 |
| FY2019 | Dec 31, 2016 | $84.67M | Feb 28, 2020 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $317.76M | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | $317.76M | Feb 25, 2026 |
| FY2024 | Dec 31, 2023 | $462.26M | Mar 17, 2025 |
| FY2023 | Dec 31, 2022 | $409.97M | Feb 28, 2024 |
| FY2022 | Dec 31, 2021 | $409.97M | Feb 28, 2023 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($2.70B) | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | ($2.15B) | Feb 25, 2026 |
| FY2024 | Dec 31, 2023 | ($1.84B) | Mar 17, 2025 |
| FY2023 | Dec 31, 2022 | ($1.53B) | Feb 28, 2024 |
| FY2022 | Dec 31, 2021 | ($1.22B) | Feb 28, 2023 |
| FY2021 | Dec 31, 2020 | ($1.04B) | Feb 28, 2022 |
| FY2020 | Dec 31, 2019 | ($1.07B) | Feb 26, 2021 |
| FY2019 | Dec 31, 2018 | ($982.11M) | Feb 28, 2020 |
| FY2018 | Jan 1, 2018 | ($879.54M) | Feb 26, 2019 |
| FY2018 | Dec 31, 2017 | ($879.73M) | Feb 26, 2019 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $63.71M | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | $55.37M | Feb 25, 2026 |
| FY2025 | Dec 31, 2023 | $179.91M | Feb 25, 2026 |
| FY2024 | Dec 31, 2022 | $325.09M | Mar 17, 2025 |
| FY2023 | Dec 31, 2021 | $460.73M | Feb 28, 2024 |
| FY2022 | Dec 31, 2020 | $81.61M | Feb 28, 2023 |
| FY2021 | Dec 31, 2019 | $29.63M | Feb 28, 2022 |
| FY2020 | Dec 31, 2018 | $18.84M | Feb 26, 2021 |
| FY2019 | Dec 31, 2017 | $16.51M | Feb 28, 2020 |
| FY2018 | Dec 31, 2016 | $16.77M | Feb 26, 2019 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2022 | Dec 31, 2022 | $896.68M | Feb 28, 2023 |
| FY2021 | Dec 31, 2021 | $896.07M | Feb 28, 2022 |
| FY2019 | Dec 31, 2019 | $15.87M | Feb 28, 2020 |
| FY2018 | Dec 31, 2018 | $14.66M | Feb 26, 2019 |
| FY2017 | Dec 31, 2017 | $13.64M | Feb 26, 2018 |
| FY2016 | Dec 31, 2016 | $16.11M | Mar 6, 2017 |
| FY2014 | Dec 31, 2014 | $14.12M | Mar 12, 2015 |
| FY2013 | Dec 31, 2013 | $13.35M | Mar 14, 2014 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (1) | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | (1) | Feb 25, 2026 |
| FY2025 | Dec 31, 2023 | (1) | Feb 25, 2026 |
| FY2024 | Dec 31, 2022 | (1) | Mar 17, 2025 |
| FY2023 | Dec 31, 2021 | 0 | Feb 28, 2024 |
| FY2022 | Dec 31, 2020 | 0 | Feb 28, 2023 |
| FY2021 | Dec 31, 2019 | 0 | Feb 28, 2022 |
| FY2020 | Dec 31, 2018 | 0 | Feb 26, 2021 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (1) | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | (1) | Feb 25, 2026 |
| FY2025 | Dec 31, 2023 | (1) | Feb 25, 2026 |
| FY2024 | Dec 31, 2022 | (1) | Mar 17, 2025 |
| FY2023 | Dec 31, 2021 | 0 | Feb 28, 2024 |
| FY2022 | Dec 31, 2020 | 0 | Feb 28, 2023 |
| FY2021 | Dec 31, 2019 | 0 | Feb 28, 2022 |
| FY2020 | Dec 31, 2018 | 0 | Feb 26, 2021 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 301.96M | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | 294.42M | Feb 25, 2026 |
| FY2024 | Dec 31, 2023 | 267.74M | Mar 17, 2025 |
| FY2023 | Dec 31, 2022 | 226.51M | Feb 28, 2024 |
| FY2022 | Dec 31, 2021 | 220.98M | Feb 28, 2023 |
| FY2021 | Dec 31, 2020 | 192.29M | Feb 28, 2022 |
| FY2020 | Dec 31, 2019 | 153.12M | Feb 26, 2021 |
| FY2019 | Dec 31, 2018 | 150.24M | Feb 28, 2020 |
| FY2018 | Dec 31, 2017 | 116.28M | Feb 26, 2019 |
| FY2017 | Dec 31, 2016 | 92.68M | Feb 26, 2018 |